Top Markets
Coin of the day
Aroa Biosurgery Limited Aroa Biosurgery Limited

Aroa Biosurgery Limited

ARX
Classement en actions #20200
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated... Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
Prix de l'action
$0.39848591
Capitalisation boursière
$137.67M
Changement (1 jour)
-1.74%
Changement (1 an)
-3.96%
Pays
NZ
Échange Aroa Biosurgery Limited (ARX)

Catégorie

Bénéfices pour Aroa Biosurgery Limited (ARX)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Aroa Biosurgery Limited, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Aroa Biosurgery Limited de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
- -
DE